4.94
price up icon0.00%   0.00
after-market Handel nachbörslich: 4.95 0.010 +0.20%
loading
Schlusskurs vom Vortag:
$4.94
Offen:
$4.97
24-Stunden-Volumen:
4.18M
Relative Volume:
0.71
Marktkapitalisierung:
$1.35B
Einnahmen:
$8.10M
Nettoeinkommen (Verlust:
$-92.72M
KGV:
-13.83
EPS:
-0.3571
Netto-Cashflow:
$-82.52M
1W Leistung:
-2.76%
1M Leistung:
+69.18%
6M Leistung:
+171.43%
1J Leistung:
+150.76%
1-Tages-Spanne:
Value
$4.91
$5.20
1-Wochen-Bereich:
Value
$4.43
$5.33
52-Wochen-Spanne:
Value
$1.05
$5.5082

Taysha Gene Therapies Inc Stock (TSHA) Company Profile

Name
Firmenname
Taysha Gene Therapies Inc
Name
Telefon
(214) 612-0000
Name
Adresse
3000 PEGASUS PARK DRIVE, DALLAS
Name
Mitarbeiter
73
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-12
Name
Neueste SEC-Einreichungen
Name
TSHA's Discussions on Twitter

Vergleichen Sie TSHA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
TSHA
Taysha Gene Therapies Inc
4.94 1.40B 8.10M -92.72M -82.52M -0.3571
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
422.63 109.29B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
464.00 62.13B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
575.69 61.40B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
812.18 51.39B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
310.03 34.68B 4.56B -176.77M 225.30M -1.7177

Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-07-11 Eingeleitet BofA Securities Buy
2024-06-27 Eingeleitet BMO Capital Markets Outperform
2024-04-09 Eingeleitet Piper Sandler Overweight
2023-02-01 Herabstufung Jefferies Buy → Hold
2023-01-27 Herabstufung Morgan Stanley Overweight → Equal-Weight
2022-11-09 Herabstufung Goldman Buy → Neutral
2022-03-09 Eingeleitet Robert W. Baird Outperform
2022-03-01 Eingeleitet Wells Fargo Overweight
2022-02-18 Eingeleitet SMBC Nikko Outperform
2021-12-16 Eingeleitet Guggenheim Buy
2021-07-16 Eingeleitet Needham Buy
2021-06-24 Eingeleitet Truist Buy
2021-06-15 Eingeleitet BTIG Research Buy
2021-06-09 Eingeleitet Wedbush Outperform
2021-06-08 Eingeleitet JMP Securities Mkt Outperform
2021-05-19 Eingeleitet Cantor Fitzgerald Overweight
2021-05-11 Fortgesetzt Jefferies Buy
2021-02-24 Eingeleitet William Blair Outperform
2021-01-05 Eingeleitet Oppenheimer Outperform
2020-10-19 Eingeleitet Chardan Capital Markets Buy
2020-10-19 Eingeleitet Goldman Buy
2020-10-19 Eingeleitet Jefferies Buy
2020-10-19 Eingeleitet Morgan Stanley Overweight
Alle ansehen

Taysha Gene Therapies Inc Aktie (TSHA) Neueste Nachrichten

pulisher
05:23 AM

Why Taysha Gene Therapies Inc. stock is rated strong buyOil Prices & Community Verified Trade Signals - newser.com

05:23 AM
pulisher
04:56 AM

Why Taysha Gene Therapies Inc. stock is favored by top institutionsPortfolio Growth Summary & Real-Time Sentiment Analysis - newser.com

04:56 AM
pulisher
01:49 AM

How institutional ownership impacts Taysha Gene Therapies Inc. stock2025 Biggest Moves & Weekly Watchlist for Hot Stocks - newser.com

01:49 AM
pulisher
Oct 22, 2025

Taysha regains full rights to TSHA-102 gene therapy for Rett - Rett Syndrome News

Oct 22, 2025
pulisher
Oct 21, 2025

Chart overlay techniques for tracking Taysha Gene Therapies Inc.Earnings Performance Report & AI Driven Stock Movement Reports - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

Candlestick signals on Taysha Gene Therapies Inc. stock todayCPI Data & Advanced Technical Analysis Signals - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

Tick level data insight on Taysha Gene Therapies Inc. volatilityQuarterly Portfolio Review & Long-Term Safe Investment Plans - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

Raymond James Initiates Coverage on TSHA with Strong Buy Rating - GuruFocus

Oct 21, 2025
pulisher
Oct 21, 2025

Taysha soars on FDA breakthrough therapy status for lead asset - MSN

Oct 21, 2025
pulisher
Oct 21, 2025

Published on: 2025-10-21 00:17:01 - newser.com

Oct 21, 2025
pulisher
Oct 20, 2025

Why Taysha Gene Therapies Inc. is moving today2025 Macro Impact & Free Accurate Trade Setup Notifications - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

Will Taysha Gene Therapies Inc. stock continue dividend increasesEarnings Summary Report & Free AI Powered Buy and Sell Recommendations - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga

Oct 20, 2025
pulisher
Oct 20, 2025

Using R and stats models for Taysha Gene Therapies Inc. forecastingJuly 2025 Levels & Risk Managed Investment Signals - newser.com

Oct 20, 2025
pulisher
Oct 19, 2025

What analysts say about Taysha Gene Therapies Inc stockStock Correlation Metrics & Zero-Cost Stock Research by Professionals - earlytimes.in

Oct 19, 2025
pulisher
Oct 19, 2025

Taysha Gene Therapies Eyes Volatility Amid Key Developments - StocksToTrade

Oct 19, 2025
pulisher
Oct 19, 2025

Taysha Gene Therapies Faces Challenging Market Following Recent Developments - timothysykes.com

Oct 19, 2025
pulisher
Oct 18, 2025

Retail Trends: Can Taysha Gene Therapies Inc. stock double in next 5 yearsJuly 2025 WrapUp & Weekly Stock Breakout Alerts - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 18, 2025

Will Taysha Gene Therapies Inc. stock maintain growth story2025 Market Sentiment & Reliable Intraday Trade Alerts - newser.com

Oct 18, 2025
pulisher
Oct 18, 2025

Taysha Gene Therapies Faces Financial Pressure: Concerns Amid Heavy Losses​ - StocksToTrade

Oct 18, 2025
pulisher
Oct 18, 2025

Taysha Gene Therapies Faces New Challenges Amid Market Volatility - timothysykes.com

Oct 18, 2025
pulisher
Oct 18, 2025

Aug Summary: Will Taysha Gene Therapies Inc. stock maintain momentum in 2025 - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 18, 2025

Weekly Earnings: Why Taysha Gene Therapies Inc. stock is seen as undervalued2025 Retail Activity & Low Drawdown Trading Strategies - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 18, 2025

What catalysts could drive Taysha Gene Therapies Inc. stock higherJuly 2025 Momentum & Weekly Watchlist for Consistent Profits - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 18, 2025

Taysha Gene Therapies Inc Stock Analysis and ForecastInstitutional Holding Changes & Affordable Portfolio Growth - earlytimes.in

Oct 18, 2025
pulisher
Oct 18, 2025

Can Taysha Gene Therapies Inc. stock hit record highs againJuly 2025 Final Week & Growth Focused Stock Pick Reports - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 17, 2025

How Regaining Full Rights to Rett Syndrome Gene Therapy Has Changed Taysha (TSHA)’s Investment Story - Yahoo Finance

Oct 17, 2025
pulisher
Oct 17, 2025

Sell Signal: Why Taysha Gene Therapies Inc. stock is seen as undervalued2025 Trade Ideas & Free Expert Verified Stock Movement Alerts - nchmf.gov.vn

Oct 17, 2025
pulisher
Oct 17, 2025

Taysha regains full rights to Rett syndrome gene therapy program By Investing.com - Investing.com Australia

Oct 17, 2025
pulisher
Oct 17, 2025

Why Is Taysha Gene Therapies Stock Falling Friday? - Sahm

Oct 17, 2025
pulisher
Oct 17, 2025

Taysha Gene Therapies regains full rights to TSHA-102 - MSN

Oct 17, 2025
pulisher
Oct 17, 2025

Earnings visualization tools for Taysha Gene Therapies Inc.Insider Buying & AI Enhanced Trade Execution Alerts - newser.com

Oct 17, 2025
pulisher
Oct 17, 2025

Bring it back home: Taysha regains gene therapy as option expires - BioWorld MedTech

Oct 17, 2025
pulisher
Oct 17, 2025

I-Mab morphs into ‘hub-and-spoke’ biotech; Astellas passes on Taysha gene therapy - BioPharma Dive

Oct 17, 2025
pulisher
Oct 17, 2025

Taysha Gene Therapies regains full rights to TSHA-102 (TSHA:NASDAQ) - Seeking Alpha

Oct 17, 2025
pulisher
Oct 17, 2025

Taysha Gene Therapies (TSHA) Rating and Price Target Reaffirmed by Chardan Capital | TSHA Stock News - GuruFocus

Oct 17, 2025
pulisher
Oct 17, 2025

Sandhoff Disease Treatment Market Size Projects USD 456.42 Million by 2034 - GlobeNewswire Inc.

Oct 17, 2025
pulisher
Oct 17, 2025

Cantor Fitzgerald reiterates Overweight rating on Taysha Gene Therapies stock - Investing.com Canada

Oct 17, 2025
pulisher
Oct 17, 2025

Needham Reiterates Taysha Gene Therapies (TSHA) with "Buy" Ratin - GuruFocus

Oct 17, 2025
pulisher
Oct 17, 2025

Taysha Gene Therapies, Inc. (TSHA) Stock Analysis: 87% Potential Upside Ignites Investor Interest - DirectorsTalk Interviews

Oct 17, 2025
pulisher
Oct 16, 2025

Taysha Gene Therapies price target raised to $9 from $8 at BofA - MSN

Oct 16, 2025
pulisher
Oct 16, 2025

Neurogene looks ‘deeply undervalued’ after Taysha news, says H.C. Wainwright - MSN

Oct 16, 2025
pulisher
Oct 16, 2025

Taysha (TSHA) Reclaims Full Rights to Key Rett Syndrome Program - GuruFocus

Oct 16, 2025
pulisher
Oct 16, 2025

Taysha Gene Therapies Regains Full Rights to TSHA-102 Program - TradingView

Oct 16, 2025
pulisher
Oct 16, 2025

Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 - GlobeNewswire

Oct 16, 2025
pulisher
Oct 16, 2025

Taysha Regains Full Rights to TSHA-102; 100% Part A Response | TSHA Stock News - Stock Titan

Oct 16, 2025

Finanzdaten der Taysha Gene Therapies Inc-Aktie (TSHA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Taysha Gene Therapies Inc-Aktie (TSHA) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Nagendran Sukumar
President and Head of R&D
Sep 10 '25
Option Exercise
0.70
41,150
28,760
1,206,439
Nagendran Sukumar
President and Head of R&D
Sep 10 '25
Sale
3.23
200,000
646,000
1,006,439
$36.85
price up icon 0.03%
$89.31
price up icon 1.42%
$29.87
price down icon 0.17%
$104.75
price down icon 1.39%
$160.12
price down icon 0.17%
biotechnology ONC
$310.03
price down icon 1.12%
Kapitalisierung:     |  Volumen (24h):